Multibagger Pharma Stock Jumps After Board Announces Record Date for 1:1 Bonus Share
The company has a market cap of over Rs 1,000 crore and the stock has given multibagger returns of 250 per cent in just 2 years.
On Wednesday, shares of Remus Pharmaceuticals Ltd jumped 4.8 per cent to Rs 1,900 per share from its previous closing of Rs 1,813.35 per share. The stock’s 52-week high is Rs 2,834.75 per share and its 52-week low is Rs 1,781.05 per share.
The Board of Remus Pharmaceuticals Limited has set Friday, July 4, 2025, as the Record Date for determining shareholder eligibility for a 1:1 bonus equity share issuance. This means that for every one existing fully paid-up equity share of Rs 10 held, shareholders will receive one new fully paid-up equity share of Rs 10. This bonus issue was approved by shareholders via postal ballot on June 23, 2025.
Incorporated in 2015, Remus Pharmaceuticals Limited operates in the trading and export of Active Pharmaceutical Ingredients (API) and Finished Formulations, alongside offering technical consultancy services. The company and its group specialise in marketing pharmaceutical products across critical care, neurology, cardiology and diabetic categories, with a recent focus on off-patent molecules and complex generics. Their business model involves getting finished pharmaceutical formulations manufactured through a loan license or contract manufacturing arrangements and their operations are divided into marketing and distribution of finished formulations globally, trading of API and providing technical consultancy for pharmaceutical dossier preparation.
DSIJ’s 'multibagger Pick’ service recommends well researched multibagger stocks with High Returns potential. If this interests you, download the service details here.
The company demonstrated robust financial performance in FY25, showcasing significant growth both year-over-year and in the second half compared to the first half. Revenue from operations for H2 FY25 reached Rs 347.75 crore, marking a 27.56 per cent increase from H1FY25's Rs 272.61 crore. Similarly, Profit After Tax (PAT) grew by 15.25 per cent from Rs 17.85 crore in H1FY25 to Rs 20.57 crore in H2FY25. On a consolidated annual basis, FY25 revenue from operations surged to Rs 620.36 crore, a remarkable 191.33 per cent increase from FY24's Rs 212.94 crore. Concurrently, PAT for FY25 saw a substantial 58.23 per cent rise, reaching Rs 38.42 crore compared to Rs 24.28 crore in FY24.
The company has a market cap of over Rs 1,000 crore and the stock has given multibagger returns of 250 per cent in just 2 years. The shares of the company have a PE of 38x, an ROE of 17 per cent and an ROCE of 23 per cent.
Disclaimer: The article is for informational purposes only and not investment advice.